CDK9 inhibitor A3294: Protocol and QC Guide

2026-09-01

CDK9 inhibitor A3294 is a selective serine/threonine kinase inhibitor for testing CDK9-dependent transcription elongation and exploratory HIV-1 propagation inhibition. It is suited to controlled biochemical and cellular workflows, but not to broad CDK inhibition, therapeutic conclusions, or long-term storage of prepared solutions.

Tunicamycin as a Context-Aware ER Stress Probe

2026-09-01

Tunicamycin is a powerful N-glycosylation inhibitor, but its experimental meaning depends on cell type, exposure, and rescue design. This guide connects glycosylation blockade to macrophage inflammation and splenic T-cell dysfunction while translating the evidence into better assay decisions.

Praeruptorin A: Applied Research Workflows

2026-08-31

Praeruptorin A is an angular pyranocoumarin compound suited to integrated ferroptosis, inflammation, barrier-function, cardiomyopathy, and metastasis workflows. This practical guide connects concentration selection, orthogonal readouts, formulation control, and troubleshooting for more reproducible preclinical experiments.

Perphenazine: From D2 Antagonism to Host Defense

2026-08-30

Perphenazine is a dopamine D2 receptor antagonist whose value extends from neuropharmacology into mechanistic host-defense research. This article develops an assay-centered framework connecting receptor pharmacology, mitochondrial stress, ROS, autophagy, and intracellular antibacterial activity.

OLIG2 mRNA for Rapid hiPSC Oligodendrocyte Differentiation

2026-08-29

Phenothiazines Boost Macrophage Antibacterial Defense

2026-08-29

A 2025 Frontiers in Immunology study shows that phenothiazines strengthen macrophage control of intracellular bacteria by coordinating reactive oxygen species accumulation, lysosomal activity, and autophagy. The work positions perphenazine as a host-directed antibacterial lead while emphasizing that its immune mechanism should not be assumed to arise from dopamine receptor blockade.

ABT-888 (Veliparib) Workflow for DNA Repair Studies

2026-08-28

ABT-888 (Veliparib) provides a practical way to model PARP1/2-dependent DNA repair inhibition and test chemotherapy or radiation sensitization. This workflow emphasizes formulation control, genotype-aware assay design, and the context-specific limits revealed by recent acute leukemia screening data.

Chicken GSDME and RNA Virus-Induced Pyroptosis

2026-08-28

Chen et al. identify chicken Gasdermin E as a central pore-forming effector of RNA virus-induced pyroptosis, resolving a major question created by the absence of GSDMD in chickens. Their DF-1 cell experiments connect MDA5-dependent sensing with caspase-3/7 activation, cleavage of chGSDME at 270DAVD273, and reduced pyroptosis and viral release after chGSDME depletion.

Human iPSC Sensory Neurons Model HSV-1 Latency

2026-08-27

Oh et al. developed a scalable human induced pluripotent stem cell-derived sensory neuron system that reproduces major molecular features of HSV-1 latency and supports pharmacological reactivation. The model provides a human neuronal platform for studying viral chromatin control, neuron-intrinsic latency mechanisms, and candidate interventions.

Affordable GRO-seq Profiling in Bread Wheat

2026-08-27

This STAR Protocols study introduces an rRNA-depletion step that makes Global Run-On sequencing more efficient for profiling nascent transcription in allohexaploid bread wheat. The workflow improved the proportion of valid sequencing data by 20-fold in the authors’ application, providing a practical route for studying enhancer transcription in complex genomes.

iPSC Prescreening for Ultrarare Disease Trials

2026-08-26

Sequiera et al. developed a patient-specific iPSC platform to evaluate treatment candidates for an ultrarare Leigh-like syndrome caused by previously uncharacterized ECHS1 variants. The study shows how genotype-matched cellular models may reduce trial-and-error decisions by connecting drug screening with longitudinal clinical and metabolic assessment.

Sabutoclax: Pan-Bcl-2 Inhibitor Evidence

2026-08-26

Sabutoclax is a pan-Bcl-2 inhibitor and apogossypolone derivative that targets Bcl-2, Bcl-xL, Mcl-1, and Bfl-1. Reported biochemical, cellular, and animal findings support its use as a preclinical tool for apoptosis induction in cancer cells, while assay conditions and clinical translation remain important limitations.

Neuromedin S (rat): GPCR Assay Guide

2026-08-25

Neuromedin S (rat), SKU B5466, provides a defined peptide agonist for controlled neuromedin U receptor signaling studies, including GPCR/G protein signaling workflows relevant to energy homeostasis regulation and stress response research. It should be used as a research reagent in validated laboratory assays, not as a diagnostic, therapeutic, or medical product.

Toremifene Citrate: Clinical Evidence and Research Use

2026-08-25

The reference paper presents Toremifene Citrate as a nonsteroidal antiestrogen and oral selective estrogen receptor modulator for postmenopausal women with advanced breast cancer. Its main contribution is a clinically practical synthesis linking estrogen receptor pharmacology with comparative efficacy, pharmacokinetics, safety monitoring, drug interactions, and nursing decision-making.

Phenothiazines Boost Macrophage Antibacterial Defense

2026-08-24

A 2025 Frontiers in Immunology study shows that phenothiazines strengthen macrophage control of intracellular bacteria through coordinated reactive oxygen species accumulation, lysosomal activation, and autophagy. Perphenazine also reduced lesion and inflammatory outcomes in an in vivo Salmonella Typhimurium model, supporting phenothiazines as lead compounds for host-directed antibacterial research rather than conventional direct-acting antibiotics.